Details of the Drug Combination

General Information of Drug Combination (ID: DC0ZWXV)

Drug Combination Name
Diethylcarbamazine Armodafinil
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Diethylcarbamazine   DM1TJ8F Armodafinil   DMGB035
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 13.25
Bliss Independence Score: 13.25
Loewe Additivity Score: 21.53
LHighest Single Agent (HSA) Score: 21.53

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Diethylcarbamazine
Disease Entry ICD 11 Status REF
Elephantiasis N.A. Approved [2]
Loiasis N.A. Approved [2]
Lymphatic filariasis 1F66.3 Approved [3]
Onchocerciasis 1F6A Approved [2]
Diethylcarbamazine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Arachidonate 5-lipoxygenase (5-LOX) TT2J34L LOX5_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Diethylcarbamazine Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Increases Activity [6]
------------------------------------------------------------------------------------
Indication(s) of Armodafinil
Disease Entry ICD 11 Status REF
Malignant glioma 2A00.0 Approved [4]
Methamphetamine dependence 6C46.2 Approved [4]
Narcolepsy 7A20 Approved [4]
Pain MG30-MG3Z Approved [4]
Pediatric cancer 2A00-2F9Z Approved [3]
Postpoliomyelitis syndrome N.A. Approved [4]
Traumatic brain injury NA07.Z Approved [4]
Armodafinil Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adrenergic receptor alpha-1D (ADRA1D) TT34BHT ADA1D_HUMAN Agonist [7]
------------------------------------------------------------------------------------
Armodafinil Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [9]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Diethylcarbamazine FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Armodafinil FDA Label
5 Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7.
6 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
7 Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
8 Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008;47(1):61-74.
9 Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet. 2003;42(2):123-37.